Portfolio company Enanta enters phase 3 clinical trial for Hepatitis C
Ad hoc Press Release
Zug, October 17, 2012
Portfolio company Enanta enters phase 3 clinical trial for Hepatitis C
Enanta Pharmaceuticals Inc., Private Equity Holding AG's largest direct investment, has announced today that ABT-450, an Enanta compound licensed to Abbott but not yet approved has entered phase 3 clinical trials for Hepatitis C (HCV) following a successful phase 2b trial. Please refer to the following press release by Enanta for more details: http://www.enanta.com/pr_101712.html .
***
Private Equity Holding AG (SIX: PEHN), managed by Alpha Associates, offers investors the opportunity to invest, within a simple legal and tax optimized structure, in a broadly diversified and professionally managed private equity portfolio.
For further information, please contact:
Peter Wolfers, Investor Relations, peter.wolfers@peh.ch, phone +41 41 726 79 80 or http://www.peh.ch.